TissGeneSummary for ZNF565 |
Gene summary |
Basic gene information | Gene symbol | ZNF565 |
Gene name | zinc finger protein 565 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 19q13.12 | |
Type of gene | protein-coding | |
RefGenes | NM_001042474.2, NM_152477.4, | |
Description | - | |
Modification date | 20141207 | |
dbXrefs | MIM : 614275 | |
HGNC : HGNC | ||
Ensembl : ENSG00000196357 | ||
HPRD : 15846 | ||
Vega : OTTHUMG00000180508 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ZNF565 | |
BioGPS: 147929 | ||
Pathway | NCI Pathway Interaction Database: ZNF565 | |
KEGG: ZNF565 | ||
REACTOME: ZNF565 | ||
Pathway Commons: ZNF565 | ||
Context | iHOP: ZNF565 | |
ligand binding site mutation search in PubMed: ZNF565 | ||
UCL Cancer Institute: ZNF565 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | PancreasTestis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | PAADTGCT | |
Reference showing the relevant tissue of ZNF565 | ||
Description by TissGene annotations | TissgsLTS Fused withOncogene |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ZNF565 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for ZNF565 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ZNF565 |
TissGeneSNV for ZNF565 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.S48P | LIHC | 1 |
p.G341R | CESC | 1 |
p.R290P | LUSC | 1 |
p.G287A | THCA | 1 |
p.V55I | UCEC | 1 |
p.G369W | LUAD | 1 |
p.S387R | BLCA | 1 |
p.G471D | COAD | 1 |
p.G247A | THCA | 1 |
p.G397R | COAD | 1 |
p.H213L | KIRP | 1 |
p.R470H | LGG | 1 |
p.R392* | HNSC | 1 |
p.E364K | BLCA | 1 |
p.P458L | SKCM | 1 |
p.E122K | ESCA | 1 |
p.R330H | HNSC | 1 |
p.E162K | BLCA | 1 |
p.E18D | STAD | 1 |
p.G409W | LUAD | 1 |
p.E404K | BLCA | 1 |
p.P390H | BRCA | 1 |
p.V11M | LIHC | 1 |
p.S193F | BLCA | 1 |
p.E376* | LIHC | 1 |
p.D110N | SARC | 1 |
p.E295Q | CESC | 1 |
p.Q394E | HNSC | 1 |
p.E336X | LIHC | 1 |
p.P334H | ESCA | 1 |
p.V74M | BLCA | 1 |
p.P474L | READ | 1 |
p.E276K | COAD | 1 |
p.L119F | SKCM | 1 |
p.Q506* | BLCA | 1 |
p.P234L | SKCM | 1 |
p.K422M | LUSC | 1 |
p.E276K | BRCA | 1 |
p.S444* | HNSC | 1 |
p.C197Y | UCEC | 1 |
p.R290H | HNSC | 1 |
p.R402C | UCEC | 1 |
p.G285S | OV | 1 |
p.R458C | BRCA | 1 |
p.H481Y | SKCM | 1 |
p.R298W | STAD | 1 |
p.Q282H | ESCA | 1 |
p.F137L | BLCA | 1 |
p.V34L | OV | 1 |
p.Y403F | HNSC | 1 |
p.R439X | THYM | 1 |
p.W115L | SARC | 1 |
p.S44L | BRCA | 1 |
p.T295N | UCEC | 1 |
p.E162K | ESCA | 1 |
Top |
TissGeneCNV for ZNF565 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ZNF565 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | ChiTaRs | NA | BF002721 | PARG-ZNF565 | chr10:51562517 | chr19:36693683 | |
TCGAfusionPortal | PRADA | OV | TCGA-25-1877-01A | AXL-ZNF565 | In-frame | Chr19:41762516 | Chr19:36686058 |
Top |
TissGeneNet for ZNF565 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ZNF565 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ZNF565 |
TissGeneDrug for ZNF565 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ZNF565 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0036341 | Schizophrenia | 1 | CTD_human |